<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01973972</url>
  </required_header>
  <id_info>
    <org_study_id>IIR 13-053</org_study_id>
    <nct_id>NCT01973972</nct_id>
  </id_info>
  <brief_title>Jump Start Shared Medical Appointments for Diabetes With Weight Management</brief_title>
  <acronym>Jump Start</acronym>
  <official_title>Jump Starting Shared Medical Appointments for Diabetes With Weight Management</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VA Office of Research and Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VA Office of Research and Development</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The proposed research will test a novel program that combines intensive weight management
      with shared (group) medical appointments for patients with diabetes. This research is
      important because diabetes is increasingly prevalent, it requires complex management by the
      provider and the patient, and weight loss is a critical component of its management. Adding
      weight management to shared medical appointments could potentially improve blood sugar
      control while reducing medications and their side effects such as low blood sugar.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Anticipated Impacts on Veteran's Healthcare: Weight management is an important focus of VA as
      evidenced by its VA/DoD Clinical Practice Guideline and MOVE! program targeting
      overweight/obesity. VA is also committed to using group visits to increase the efficiency and
      effectiveness of health care delivery. The investigators aim to test a novel intervention
      that combines intensive weight and diabetes management using the SMA platform. This research
      addresses important missions to VA because diabetes is more prevalent in Veterans than in the
      general population, and because weight management is more challenging and complex in patients
      with diabetes. Project Background: SMAs involve groups of patients who share a common chronic
      condition and meet over time to receive education, self-management enhancement, and
      medication management to improve clinical outcomes. A systematic review by VA found that SMAs
      modestly improve glycemia in patients with diabetes. Although these SMA programs sometimes
      included diet and physical activity counseling, weight management was not a primary goal, and
      weight typically was not reduced. Instead, medication intensification was the primary
      strategy for improving glycemia, and this strategy can lead to weight gain.

      For overweight patients with diabetes, weight loss is first-line therapy because it can
      improve glycemic control and because excess weight leads to poorer outcomes. Moreover, many
      antiglycemic medications cause weight gain and hypoglycemic events, which may counteract the
      potential macrovascular benefits of glycemic control. Dietary interventions, however, can
      lower weight and improve glycemic control while reducing antiglycemic medication needs and,
      therefore, subsequent risk for hypoglycemic episodes.

      In prior research, the investigators induced weight loss and improved glycemic control while
      decreasing antiglycemic medications. A combination of an intensive weight management program
      with the diabetes management offered in SMAs has potential to further improve diabetes
      outcomes, reduce complications, decrease costs and increase health-related quality of life.
      Such a combined intervention is ideal for patients with diabetes because of their unique
      dietary considerations, and their need for careful glycemic and medication management during
      weight loss. Project Objectives: The investigators will examine whether an intensive,
      group-based weight management program followed by an SMA intervention (WM/SMA arm) is
      comparably effective (non-inferior) to the SMA intervention alone for improving glycemic
      control while using less antiglycemic medication and resulting in fewer hypoglycemic events
      and lower healthcare costs. Project Methods: 308 overweight VA outpatients with uncontrolled
      (hemoglobin A1c 8.0% or 7.5% or greater for those under 50) type 2 diabetes will participate
      in this RCT. Similar to prior SMAs, the SMA visits will occur every 4 weeks for 16 weeks and
      then every 8 weeks for 32 weeks for a total of 9 visits. Sessions will be led by a physician
      and trained interventionists, and will include educational topics related to diabetes
      management (including diet and physical activity), self-management training, and medication
      adjustment. Similar to the investigators' prior weight management trials, the WM/SMA group
      will meet every 2 weeks for 16 weeks and then every 8 weeks for 32 weeks for a total of 13
      visits. The weight management program will focus on a low carbohydrate dietary pattern
      because of its potential to lower glycemia, leading to reduced antiglycemic medication needs.
      After 16 weeks, meeting content will shift to the SMA intervention content but weight
      management will continue to be addressed at the meetings. The primary outcome is glycemic
      control assessed by hemoglobin A1c assessed at baseline and at 16, 32, and 48 weeks.
      Secondary outcomes include hypoglycemic events, changes in the antiglycemic medication
      regimen as assessed by a summary score, weight and healthcare costs. Diabetes-specific
      health-related quality of life and medication adherence will also be assessed.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 12, 2014</start_date>
  <completion_date type="Actual">July 31, 2018</completion_date>
  <primary_completion_date type="Actual">July 31, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hemoglobin A1c</measure>
    <time_frame>48 weeks</time_frame>
    <description>measure of glycemic control</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hypoglycemic Events</measure>
    <time_frame>through 48 weeks</time_frame>
    <description>All episodes of hypoglycemia will be recorded by participants on provided standard log forms, noting the date, time, duration, symptoms, treatment received, and concurrent blood glucose. Participants will additionally be asked if they received medical attention for hypoglycemia, and the details if so, since the last assessment. Only one episode will be counted per 24 hours. Serious episodes, defined as &lt;50 mg/dL or 50-69 mg/dL and requiring assistance, will supersede minor episodes in this case.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medication Effect Score</measure>
    <time_frame>48 weeks</time_frame>
    <description>Antiglycemic medications, dosages, and schedules will be assessed carefully with the participant and updated at each visit. A Medication Effect Score (MES), based on the potencies and dosages of the medications in a patient's regimen, was devised to reflect the overall intensity of antiglycemic medication. The MES is calculated as the percentage taken of the maximum dose multiplied by the expected hemoglobin A1c lowering effect for each of a participant's medications, which are then summed. Its range is 0 to infinite, with higher scores meaning higher diabetes medication requirement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight</measure>
    <time_frame>48 weeks</time_frame>
    <description>weight by electronic scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimated Costs of Intervention Strategies</measure>
    <time_frame>through 48 weeks</time_frame>
    <description>Estimates of intervention costs, utilities, direct and indirect costs using market lab cost estimates</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">263</enrollment>
  <condition>Diabetes</condition>
  <arm_group>
    <arm_group_label>Weight management/shared medical appointment (WM/SMA)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Weight management group visits every 2 weeks for 16 weeks using low-carbohydrate diet followed by group visits every 8 weeks (total of 48 weeks) for weight and diabetes management.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Shared medical appointments (SMA)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Diabetes management group visits every 4 weeks for 16 weeks followed by group visits every 8 weeks (total of 48 weeks) for diabetes management.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Weight management</intervention_name>
    <description>Weight management group visits using low-carbohydrate diet followed for weight management.</description>
    <arm_group_label>Weight management/shared medical appointment (WM/SMA)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Shared medical appointments (SMA)</intervention_name>
    <description>Diabetes management group visits for diabetes management.</description>
    <arm_group_label>Shared medical appointments (SMA)</arm_group_label>
    <arm_group_label>Weight management/shared medical appointment (WM/SMA)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of type 2 diabetes,

          -  Hemoglobin A1c &gt;= 8.0% or , &gt;= 7.5 for those less than 50

          -  BMI &gt;= 27 kg/m2,

          -  Interest in losing weight,

          -  Agrees to attend regular visits per study protocol,

          -  Has access to reliable transportation,

          -  Has a VAMC provider.

        Exclusion Criteria:

          -  Age &gt;= 75 years old,

          -  Hemoglobinopathy that interferes with measurement of hemoglobin A1c,

          -  Certain chronic or unstable diseases that may put the participant at increased risk.
             These include the following:

               -  Kidney disease (serum creatinine &gt;1.5 mg/dL in men, &gt;1.3 mg/dL in women),

               -  Type 1 diabetes,

               -  Unstable CHD (unstable angina, current/active coronary ischemia workup),

               -  Blood pressure 160/100 mm Hg,

               -  Fasting triglycerides 600 mg/dL,

               -  Fasting serum LDL-C 190 mg/dL,

          -  Pregnancy, breastfeeding, or lack of birth control if premenopausal,

          -  Dementia, psychiatric illness, or substance abuse that may interfere with adherence
             (e.g. illness that is currently unstable or resistant to first-line therapy; substance
             abuse in the past year),

          -  Enrollment in another research study that might affect the main outcomes of this
             study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William S Yancy, MD MHS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Durham VA Medical Center, Durham, NC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Durham VA Medical Center, Durham, NC</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Crowley MJ, Edelman D, Voils CI, Maciejewski ML, Coffman CJ, Jeffreys AS, Turner MJ, Gaillard LA, Hinton TA, Strawbridge E, Zervakis J, Barton AB, Yancy WS Jr. Jump starting shared medical appointments for diabetes with weight management: Rationale and design of a randomized controlled trial. Contemp Clin Trials. 2017 Jul;58:1-12. doi: 10.1016/j.cct.2017.04.004. Epub 2017 Apr 23.</citation>
    <PMID>28445783</PMID>
  </results_reference>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>October 18, 2013</study_first_submitted>
  <study_first_submitted_qc>October 25, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 1, 2013</study_first_posted>
  <results_first_submitted>June 27, 2019</results_first_submitted>
  <results_first_submitted_qc>August 12, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">September 16, 2019</results_first_posted>
  <last_update_submitted>September 17, 2019</last_update_submitted>
  <last_update_submitted_qc>September 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetes</keyword>
  <keyword>Obesity</keyword>
  <keyword>Complex Care</keyword>
  <keyword>Primary Care</keyword>
  <keyword>Chronic Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 20, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/72/NCT01973972/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Weight Management/Shared Medical Appointment (WM/SMA)</title>
          <description>Weight management group visits every 2 weeks for 16 weeks using low-carbohydrate diet followed by group visits every 8 weeks (total of 48 weeks) for weight and diabetes management.
Weight management: Weight management group visits using low-carbohydrate diet followed for weight management.
Shared medical appointments (SMA): Diabetes management group visits for diabetes management.</description>
        </group>
        <group group_id="P2">
          <title>Shared Medical Appointments (SMA)</title>
          <description>Diabetes management group visits every 4 weeks for 16 weeks followed by group visits every 8 weeks (total of 48 weeks) for diabetes management.
Shared medical appointments (SMA): Diabetes management group visits for diabetes management.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="127"/>
                <participants group_id="P2" count="136"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="109"/>
                <participants group_id="P2" count="117"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Weight Management/Shared Medical Appointment (WM/SMA)</title>
          <description>Weight management group visits every 2 weeks for 16 weeks using low-carbohydrate diet followed by group visits every 8 weeks (total of 48 weeks) for weight and diabetes management.
Weight management: Weight management group visits using low-carbohydrate diet followed for weight management.
Shared medical appointments (SMA): Diabetes management group visits for diabetes management.</description>
        </group>
        <group group_id="B2">
          <title>Shared Medical Appointments (SMA)</title>
          <description>Diabetes management group visits every 4 weeks for 16 weeks followed by group visits every 8 weeks (total of 48 weeks) for diabetes management.
Shared medical appointments (SMA): Diabetes management group visits for diabetes management.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="127"/>
            <count group_id="B2" value="136"/>
            <count group_id="B3" value="263"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.0" spread="8.1"/>
                    <measurement group_id="B2" value="60.4" spread="8.3"/>
                    <measurement group_id="B3" value="60.7" spread="8.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="110"/>
                    <measurement group_id="B2" value="125"/>
                    <measurement group_id="B3" value="235"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="64"/>
                    <measurement group_id="B2" value="79"/>
                    <measurement group_id="B3" value="143"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                    <measurement group_id="B2" value="52"/>
                    <measurement group_id="B3" value="112"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="127"/>
                    <measurement group_id="B2" value="136"/>
                    <measurement group_id="B3" value="263"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hemoglobin A1c</title>
          <units>percentage of glycosylated hemoglobin</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9.0" spread="1.3"/>
                    <measurement group_id="B2" value="9.2" spread="1.3"/>
                    <measurement group_id="B3" value="9.1" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body mass index</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35.6" spread="5.4"/>
                    <measurement group_id="B2" value="35.0" spread="4.8"/>
                    <measurement group_id="B3" value="35.3" spread="5.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Hemoglobin A1c</title>
        <description>measure of glycemic control</description>
        <time_frame>48 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Weight Management/Shared Medical Appointment (WM/SMA)</title>
            <description>Weight management group visits every 2 weeks for 16 weeks using low-carbohydrate diet followed by group visits every 8 weeks (total of 48 weeks) for weight and diabetes management.
Weight management: Weight management group visits using low-carbohydrate diet followed for weight management.
Shared medical appointments (SMA): Diabetes management group visits for diabetes management.</description>
          </group>
          <group group_id="O2">
            <title>Shared Medical Appointments (SMA)</title>
            <description>Diabetes management group visits every 4 weeks for 16 weeks followed by group visits every 8 weeks (total of 48 weeks) for diabetes management.
Shared medical appointments (SMA): Diabetes management group visits for diabetes management.</description>
          </group>
        </group_list>
        <measure>
          <title>Hemoglobin A1c</title>
          <description>measure of glycemic control</description>
          <units>percentage of glycosylated hemoglobin</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="127"/>
                <count group_id="O2" value="136"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.2" spread="1.6"/>
                    <measurement group_id="O2" value="8.3" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hypoglycemic Events</title>
        <description>All episodes of hypoglycemia will be recorded by participants on provided standard log forms, noting the date, time, duration, symptoms, treatment received, and concurrent blood glucose. Participants will additionally be asked if they received medical attention for hypoglycemia, and the details if so, since the last assessment. Only one episode will be counted per 24 hours. Serious episodes, defined as &lt;50 mg/dL or 50-69 mg/dL and requiring assistance, will supersede minor episodes in this case.</description>
        <time_frame>through 48 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Weight Management/Shared Medical Appointment (WM/SMA)</title>
            <description>Weight management group visits every 2 weeks for 16 weeks using low-carbohydrate diet followed by group visits every 8 weeks (total of 48 weeks) for weight and diabetes management.
Weight management: Weight management group visits using low-carbohydrate diet followed for weight management.
Shared medical appointments (SMA): Diabetes management group visits for diabetes management.</description>
          </group>
          <group group_id="O2">
            <title>Shared Medical Appointments (SMA)</title>
            <description>Diabetes management group visits every 4 weeks for 16 weeks followed by group visits every 8 weeks (total of 48 weeks) for diabetes management.
Shared medical appointments (SMA): Diabetes management group visits for diabetes management.</description>
          </group>
        </group_list>
        <measure>
          <title>Hypoglycemic Events</title>
          <description>All episodes of hypoglycemia will be recorded by participants on provided standard log forms, noting the date, time, duration, symptoms, treatment received, and concurrent blood glucose. Participants will additionally be asked if they received medical attention for hypoglycemia, and the details if so, since the last assessment. Only one episode will be counted per 24 hours. Serious episodes, defined as &lt;50 mg/dL or 50-69 mg/dL and requiring assistance, will supersede minor episodes in this case.</description>
          <units>events</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="127"/>
                <count group_id="O2" value="136"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2" lower_limit="2.1" upper_limit="4.4"/>
                    <measurement group_id="O2" value="6.6" lower_limit="4.5" upper_limit="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Medication Effect Score</title>
        <description>Antiglycemic medications, dosages, and schedules will be assessed carefully with the participant and updated at each visit. A Medication Effect Score (MES), based on the potencies and dosages of the medications in a patient's regimen, was devised to reflect the overall intensity of antiglycemic medication. The MES is calculated as the percentage taken of the maximum dose multiplied by the expected hemoglobin A1c lowering effect for each of a participant's medications, which are then summed. Its range is 0 to infinite, with higher scores meaning higher diabetes medication requirement.</description>
        <time_frame>48 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Weight Management/Shared Medical Appointment (WM/SMA)</title>
            <description>Weight management group visits every 2 weeks for 16 weeks using low-carbohydrate diet followed by group visits every 8 weeks (total of 48 weeks) for weight and diabetes management.
Weight management: Weight management group visits using low-carbohydrate diet followed for weight management.
Shared medical appointments (SMA): Diabetes management group visits for diabetes management.</description>
          </group>
          <group group_id="O2">
            <title>Shared Medical Appointments (SMA)</title>
            <description>Diabetes management group visits every 4 weeks for 16 weeks followed by group visits every 8 weeks (total of 48 weeks) for diabetes management.
Shared medical appointments (SMA): Diabetes management group visits for diabetes management.</description>
          </group>
        </group_list>
        <measure>
          <title>Medication Effect Score</title>
          <description>Antiglycemic medications, dosages, and schedules will be assessed carefully with the participant and updated at each visit. A Medication Effect Score (MES), based on the potencies and dosages of the medications in a patient's regimen, was devised to reflect the overall intensity of antiglycemic medication. The MES is calculated as the percentage taken of the maximum dose multiplied by the expected hemoglobin A1c lowering effect for each of a participant's medications, which are then summed. Its range is 0 to infinite, with higher scores meaning higher diabetes medication requirement.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="127"/>
                <count group_id="O2" value="136"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.2" spread="1.5"/>
                    <measurement group_id="O2" value="2.7" spread="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Weight</title>
        <description>weight by electronic scale</description>
        <time_frame>48 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Weight Management/Shared Medical Appointment (WM/SMA)</title>
            <description>Weight management group visits every 2 weeks for 16 weeks using low-carbohydrate diet followed by group visits every 8 weeks (total of 48 weeks) for weight and diabetes management.
Weight management: Weight management group visits using low-carbohydrate diet followed for weight management.
Shared medical appointments (SMA): Diabetes management group visits for diabetes management.</description>
          </group>
          <group group_id="O2">
            <title>Shared Medical Appointments (SMA)</title>
            <description>Diabetes management group visits every 4 weeks for 16 weeks followed by group visits every 8 weeks (total of 48 weeks) for diabetes management.
Shared medical appointments (SMA): Diabetes management group visits for diabetes management.</description>
          </group>
        </group_list>
        <measure>
          <title>Weight</title>
          <description>weight by electronic scale</description>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="127"/>
                <count group_id="O2" value="136"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="104.3" spread="20.3"/>
                    <measurement group_id="O2" value="108.0" spread="19.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Estimated Costs of Intervention Strategies</title>
        <description>Estimates of intervention costs, utilities, direct and indirect costs using market lab cost estimates</description>
        <time_frame>through 48 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Weight Management/Shared Medical Appointment (WM/SMA)</title>
            <description>Weight management group visits every 2 weeks for 16 weeks using low-carbohydrate diet followed by group visits every 8 weeks (total of 48 weeks) for weight and diabetes management.
Weight management: Weight management group visits using low-carbohydrate diet followed for weight management.
Shared medical appointments (SMA): Diabetes management group visits for diabetes management.</description>
          </group>
          <group group_id="O2">
            <title>Shared Medical Appointments (SMA)</title>
            <description>Diabetes management group visits every 4 weeks for 16 weeks followed by group visits every 8 weeks (total of 48 weeks) for diabetes management.
Shared medical appointments (SMA): Diabetes management group visits for diabetes management.</description>
          </group>
        </group_list>
        <measure>
          <title>Estimated Costs of Intervention Strategies</title>
          <description>Estimates of intervention costs, utilities, direct and indirect costs using market lab cost estimates</description>
          <units>U.S. dollars</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="127"/>
                <count group_id="O2" value="136"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1513.42" lower_limit="1451.34" upper_limit="1575.49"/>
                    <measurement group_id="O2" value="1264.49" lower_limit="1204.39" upper_limit="1324.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>48 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Weight Management/Shared Medical Appointment (WM/SMA)</title>
          <description>Weight management group visits every 2 weeks for 16 weeks using low-carbohydrate diet followed by group visits every 8 weeks (total of 48 weeks) for weight and diabetes management.
Weight management: Weight management group visits using low-carbohydrate diet followed for weight management.
Shared medical appointments (SMA): Diabetes management group visits for diabetes management.</description>
        </group>
        <group group_id="E2">
          <title>Shared Medical Appointments (SMA)</title>
          <description>Diabetes management group visits every 4 weeks for 16 weeks followed by group visits every 8 weeks (total of 48 weeks) for diabetes management.
Shared medical appointments (SMA): Diabetes management group visits for diabetes management.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="136"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>percutaneous coronary intervention</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>pacemaker replacement</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>coronary catheterization</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>atrial fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>heart attack</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>congestive heart failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>angina</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>pacemaker firing</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>death/heart attack</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>coronary artery disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="136"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>hypoglycemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>hyperglycemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="136"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>rectal bleeding</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>bowel obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>chest pain/GERD</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>hemetemesis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>death/esophageal tear</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>pancreatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>death/cirrhosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>bedbug infestation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>sepsis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>bacterial peritonitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>flu-like illness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>fournier's gangrene</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="136"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>angioedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>coccyx injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>arm fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="136"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>hyperkalemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>hand injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>muscle pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>prostate cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>pancreatic cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="136"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>suicidal ideation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="136"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>urinary obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="136"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>chest pain/URI</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>gallbladder surgery</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>joint replacement</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>urologic surgery</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>prostate cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>lumbar fusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="136"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>carotid endarterectomy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>hypotension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>severe hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>stroke</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="127"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="136"/>
              </event>
              <event>
                <sub_title>death/stroke</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="127"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="136"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="127"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="136"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>hypomagnesemia</sub_title>
                <counts group_id="E1" events="15" subjects_affected="12" subjects_at_risk="127"/>
                <counts group_id="E2" events="11" subjects_affected="9" subjects_at_risk="136"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Original target N not reached due to limited eligible and interested patients. Updated sample size calculation assuming 15% attrition and 1.4% standard deviation for hemoglobin A1c yielded N=254 for 80% power for the non-inferiority hypothesis.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>William S. Yancy, Jr.</name_or_title>
      <organization>Duke University</organization>
      <phone>919-681-2863</phone>
      <email>yancy006@mc.duke.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

